M&A activity snapshot
Plastics processing remains an active M&A niche. PMCF counted 234 announced global plastics transactions in the first half of 2026, 27 more than the prior-year period and 24% above the trailing three-year first-half average. The same tracker shows a split market: domestic activity is down roughly 10% from 2025 levels even as foreign-to-foreign deals rose.
By process, injection molding remained the largest manufacturing process in the first half of 2026, with transaction volume increasing 8% year over year, according to Stout. In the same data, extrusion activity increased 50%, while resin and compounding activity declined 37%.
This page covers custom molders, extruders and rubber component makers. Most sit in NAICS 326199, All Other Plastics Product Manufacturing, or 326291, Rubber Product Manufacturing for Mechanical Use. Packaging film, bottles and containers are covered on the separate packaging page.
Who is buying
Strategics still do most of the deals. In Stout's data, strategic buyer activity represented most of the transaction volume in the first half of 2026 despite a 21% decline, while hybrid buyers (sponsor-owned strategics) grew 36%. PMCF's June count showed add-ons increasing approximately 17% to 68 deals year to date, the fastest-growing buyer type.
Healthcare-focused private equity is a distinct buyer group for medical molders. Stout advised Currier Plastics on its sale to Sheridan Capital Partners, a Chicago healthcare investor with 18 platforms and 180+ add-on investments. Lower-middle-market sponsors build molding platforms through add-ons, such as Blackford Capital's acquisition of Industrial Molding Corp. as the first add-on for Davalor Mold Co. Family holding companies also buy, as in Viking Plastics' sale to the Hoffmann Family of Companies.
What buyers look for
Pricing power on resin comes first. The 2026 supply shock pushed certain resin prices to multi-year highs, and Stout reports that processors with pass-through mechanisms moved the cost to customers. A seller should be able to show written resin indexing clauses and a history of recovering increases on schedule.
End market and certification come next. PMCF notes that medical, aerospace & defense, electronics, food packaging, and certain consumer products demonstrate greater resiliency. For medical work, FDA's QMSR, effective February 2, 2026, incorporates ISO 13485:2016 by reference. Automotive customers expect suppliers to hold IATF 16949, the automotive quality management standard.
Tooling ownership is a routine diligence question for custom molders. Buyers want a mold list showing which tools the customer owns, which the molder owns, and who pays for maintenance and replacement. Ambiguity there can become a purchase-price or working-capital dispute.
What makes a strong company
Operating data separates premium processors from the rest. Stout, citing Wipfli benchmarking, reports that plastics processors returned a median EBITDA margin of 10.2% in 2025, roughly 250 bps ahead of the manufacturing median. The same study found processors ran at 60% uptime, well behind assembly at 78%, with unscheduled downtime eating 16% of available machine time.
Size is not the main gate. Two thirds of the top-performing facilities in the Wipfli study generate less than $20 million of revenue. The KPIs buyers ask for follow from that data:
- Press-level utilization and unplanned downtime, tracked by machine rather than estimated.
- Scrap rate and cost-of-quality tracking, with customer return and PPM history.
- Resin pass-through or index clauses in the major customer contracts.
- A clean tooling register separating customer-owned from company-owned molds.
- Current ISO 13485 or IATF 16949 certificates where the end market requires them.
Valuation and deal structure
Disclosed private multiples are scarce and volatile. R.L. Hulett's PitchBook data showed the median reported strategic EV/EBITDA multiple falling to 3.7x in Q1 2026 from 5.1x in 2025, with no private equity multiples reported. That figure reflects a small, global set of disclosed deals and should not be read as a typical lower-middle-market price.
End market drives the spread. In public markets, Stout found multiples for six of the eight plastics subsectors were up in the first half of 2026, led by Plastic Pipe & Conduit, while Medical experienced the steepest contraction from historically elevated levels. Public-market input costs also split the chain: PMCF noted processing company valuations declining by over 10 percent while resin suppliers gained more than 20 percent.
On structure, sponsor platforms commonly use management rollover and earnouts, but none of the sources above break out their frequency for plastics deals. Treat them as general middle-market practice rather than a sourced plastics norm.
Outlook
Stout expects that deal activity should reaccelerate as resin pricing stabilizes, but with more selective capital as rates stay higher for longer. Labor is the structural pressure: unlike resin, Stout notes that labor cost does not pass through cleanly, so automation and workforce stability weigh more in valuation.
For owners, the first half of 2026 is now evidence. A processor that held margin through the resin spike, and can show it in contract terms and monthly results, has the strongest case to make to buyers in the coming deal cycle.
Own a plastics or rubber processing business and want a market-data starting point? Run the valuation tool or see the full manufacturing M&A overview. See also: why vertical-specific buyers outperform generalists in outbound.